Edition:
United Kingdom

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

30.00USD
3:32pm BST
Change (% chg)

$-0.08 (-0.27%)
Prev Close
$30.08
Open
$29.97
Day's High
$30.08
Day's Low
$29.79
Volume
24,947
Avg. Vol
453,093
52-wk High
$53.38
52-wk Low
$24.45

Select another date:

Wed, Mar 28 2018

BRIEF-The Medicines Company Announces Chief Financial Officer Transition

* THE MEDICINES COMPANY ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION

BRIEF-Medicines Co Says Board Appointed Christopher Visioli As CFO

* MEDICINES - ON MARCH 21, BOARD APPOINTED CHRISTOPHER VISIOLI CFO AND TREASURER OF COMPANY, EFFECTIVE IMMEDIATELY

Medicines Company cuts board size, activist Denner to get more control

Medicines Company on Thursday said it was cutting the number of directors on its board, a move that could give billionaire investor Alex Denner greater control.

Medicines Company cuts board size, activist Denner to get more control

March 1 Medicines Company on Thursday said it was cutting the number of directors on its board, a move that could give billionaire investor Alex Denner greater control.

BRIEF-The Medicines Company Appoints Sarah Schlesinger To Its Board Of Directors

* THE MEDICINES COMPANY APPOINTS SARAH SCHLESINGER TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-The Medicines Q4 GAAP Loss Per Share $2.19 From Continuing Operations

* THE MEDICINES COMPANY REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 BUSINESS AND FINANCIAL RESULTS

BRIEF-The Medicines Company Reaches Enrollment Target For Orion-9 Ahead Of Schedule

* THE MEDICINES COMPANY REACHES ENROLLMENT TARGET FOR ORION-9 AHEAD OF SCHEDULE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Medicines Co Reports 10.6 Pct Passive Stake In Melinta Therapeutics

* THE MEDICINES COMPANY REPORTS 10.6 PERCENT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN. 5, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2muRQBT) Further company coverage:

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

Select another date: